These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9990467)

  • 1. Prodrugs for targeting hypoxic tissues: regiospecific elimination of aspirin from reduced indolequinones.
    Jaffar M; Everett SA; Naylor MA; Moore SG; Ulhaq S; Patel KB; Stratford MR; Nolan J; Wardman P; Stratford IJ
    Bioorg Med Chem Lett; 1999 Jan; 9(1):113-8. PubMed ID: 9990467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioreductively-activated prodrugs for targeting hypoxic tissues: elimination of aspirin from 2-nitroimidazole derivatives.
    Everett SA; Naylor MA; Patel KB; Stratford MR; Wardman P
    Bioorg Med Chem Lett; 1999 May; 9(9):1267-72. PubMed ID: 10340612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indolequinone antitumor agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro.
    Naylor MA; Swann E; Everett SA; Jaffar M; Nolan J; Robertson N; Lockyer SD; Patel KB; Dennis MF; Stratford MR; Wardman P; Adams GE; Moody CJ; Stratford IJ
    J Med Chem; 1998 Jul; 41(15):2720-31. PubMed ID: 9667963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modifying rates of reductive elimination of leaving groups from indolequinone prodrugs: a key factor in controlling hypoxia-selective drug release.
    Everett SA; Swann E; Naylor MA; Stratford MR; Patel KB; Tian N; Newman RG; Vojnovic B; Moody CJ; Wardman P
    Biochem Pharmacol; 2002 May; 63(9):1629-39. PubMed ID: 12007566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indolequinone bioreductive drugs: kinetic factors which influence selectivity for hypoxia.
    Everett SA; Naylor MA; Nolan J; Patel KB; Wardman P
    Anticancer Drug Des; 1998 Sep; 13(6):635-53. PubMed ID: 9755722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones.
    Bailey SM; Suggett N; Walton MI; Workman P
    Int J Radiat Oncol Biol Phys; 1992; 22(4):649-53. PubMed ID: 1544832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinone bioreductive prodrugs as delivery agents.
    Jaffar M; Abou-Zeid N; Bai L; Mrema I; Robinson I; Tanner R; Stratford IJ
    Curr Drug Deliv; 2004 Oct; 1(4):345-50. PubMed ID: 16305396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents.
    Tercel M; Atwell GJ; Yang S; Stevenson RJ; Botting KJ; Boyd M; Smith E; Anderson RF; Denny WA; Wilson WR; Pruijn FB
    J Med Chem; 2009 Nov; 52(22):7258-72. PubMed ID: 19877646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the mechanisms of activation of indolequinone phosphoramidate prodrugs.
    Hernick M; Borch RF
    J Med Chem; 2003 Jan; 46(1):148-54. PubMed ID: 12502368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxic selectivity and solubility--investigating the properties of A-ring substituted nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-ones (nitroCBIs) as hypoxia-activated prodrugs for antitumor therapy.
    Tercel M; Yang S; Atwell GJ; Smith E; Gu Y; Anderson RF; Denny WA; Wilson WR; Pruijn FB
    Bioorg Med Chem; 2010 Jul; 18(14):4997-5006. PubMed ID: 20580559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitro seco analogues of the duocarmycins containing sulfonate leaving groups as hypoxia-activated prodrugs for cancer therapy.
    Stevenson RJ; Denny WA; Tercel M; Pruijn FB; Ashoorzadeh A
    J Med Chem; 2012 Mar; 55(6):2780-802. PubMed ID: 22339090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of sulfonate leaving groups on the hypoxia-selective toxicity of nitro analogs of the duocarmycins.
    Ashoorzadeh A; Atwell GJ; Pruijn FB; Wilson WR; Tercel M; Denny WA; Stevenson RJ
    Bioorg Med Chem; 2011 Aug; 19(16):4851-60. PubMed ID: 21767954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro.
    Jaffar M; Phillips RM; Williams KJ; Mrema I; Cole C; Wind NS; Ward TH; Stratford IJ; Patterson AV
    Biochem Pharmacol; 2003 Oct; 66(7):1199-206. PubMed ID: 14505799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Nitro and 4-nitro-quinone-methides are not irreversible inhibitors of bovine beta-glucuronidase.
    Azoulay M; Chalard F; Gesson JP; Florent JC; Monneret C
    Carbohydr Res; 2001 May; 332(2):151-6. PubMed ID: 11434372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours.
    McNally VA; Patterson AV; Williams KJ; Cowen RL; Stratford IJ; Jaffar M
    Curr Pharm Des; 2002; 8(15):1319-33. PubMed ID: 12052210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships.
    Phillips RM; Naylor MA; Jaffar M; Doughty SW; Everett SA; Breen AG; Choudry GA; Stratford IJ
    J Med Chem; 1999 Oct; 42(20):4071-80. PubMed ID: 10514277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-nitroimidazol-5-ylmethyl as a potential bioreductively activated prodrug system: reductively triggered release of the PARP inhibitor 5-bromoisoquinolinone.
    Parveen I; Naughton DP; Whish WJ; Threadgill MD
    Bioorg Med Chem Lett; 1999 Jul; 9(14):2031-6. PubMed ID: 10450975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: structure-activity in vitro and efficacy in vivo.
    Naylor MA; Jaffar M; Nolan J; Stephens MA; Butler S; Patel KB; Everett SA; Adams GE; Stratford IJ
    J Med Chem; 1997 Jul; 40(15):2335-46. PubMed ID: 9240349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.
    Hunter FW; Jaiswal JK; Hurley DG; Liyanage HD; McManaway SP; Gu Y; Richter S; Wang J; Tercel M; Print CG; Wilson WR; Pruijn FB
    Biochem Pharmacol; 2014 May; 89(2):224-35. PubMed ID: 24632291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of anticancer prodrugs for reductive activation.
    Chen Y; Hu L
    Med Res Rev; 2009 Jan; 29(1):29-64. PubMed ID: 18688784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.